Astrazeneca gets marketing authorisation to use anti-diabetes drug for kidney disease

The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with CKD, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cSA4DI
via IFTTT